Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results
Company-Specific Issues Limit Any Third-Quarter Conclusions
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
